- Home
- EHTH vs ACIU Comparison
EHTH vs ACIU Comparison
Compare EHTH & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHTH
- ACIU
- Stock Information
- Founded
- EHTH 1997
- ACIU 2003
- Country
- EHTH United States
- ACIU Switzerland
- Employees
- EHTH N/A
- ACIU N/A
- Industry
- EHTH Specialty Insurers
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- EHTH Finance
- ACIU Health Care
- Exchange
- EHTH Nasdaq
- ACIU Nasdaq
- Market Cap
- EHTH 292.7M
- ACIU 247.4M
- IPO Year
- EHTH 2006
- ACIU 2016
- Fundamental
- Price
- EHTH $7.73
- ACIU $2.30
- Analyst Decision
- EHTH Hold
- ACIU Strong Buy
- Analyst Count
- EHTH 5
- ACIU 2
- Target Price
- EHTH $7.70
- ACIU $12.00
- AVG Volume (30 Days)
- EHTH 325.3K
- ACIU 207.4K
- Earning Date
- EHTH 05-06-2025
- ACIU 05-12-2025
- Dividend Yield
- EHTH N/A
- ACIU N/A
- EPS Growth
- EHTH N/A
- ACIU N/A
- EPS
- EHTH N/A
- ACIU N/A
- Revenue
- EHTH $532,409,999.00
- ACIU $48,505,404.00
- Revenue This Year
- EHTH $1.50
- ACIU $86.78
- Revenue Next Year
- EHTH $8.74
- ACIU $118.22
- P/E Ratio
- EHTH N/A
- ACIU N/A
- Revenue Growth
- EHTH 17.56
- ACIU 4097200.00
- 52 Week Low
- EHTH $3.58
- ACIU $2.19
- 52 Week High
- EHTH $11.36
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- EHTH 36.06
- ACIU 36.75
- Support Level
- EHTH $7.51
- ACIU $2.19
- Resistance Level
- EHTH $8.44
- ACIU $2.55
- Average True Range (ATR)
- EHTH 0.63
- ACIU 0.13
- MACD
- EHTH -0.17
- ACIU -0.02
- Stochastic Oscillator
- EHTH 8.46
- ACIU 21.57
About EHTH eHealth Inc.
eHealth Inc is a company involved in private health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. The company operates its business in two segments: Medicare and Employer and Individual. It derives maximum revenue from Medicare Segment. All of the company's revenue is from the United States. It also has a presence in China.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.